Results 181 to 190 of about 104,861 (298)

PARP inhibitors in gastric cancer: unlocking precision oncology. [PDF]

Oncologist
Tai D, Goes V, Kumar S, Shah P, Al-Manaseer F, Park D, Crook C, Guzman S, Zhu X, Li D, Castillo D.   +10 more
europepmc   +1 more source

Expanding the horizons of PARP inhibitors [PDF]

Nature Reviews Cancer, 2010
openaire   +2 more sources

Malignant craniopharyngiomas: Institutional experience and literature review

Brain Pathology, EarlyView.
We report the second case of malignant craniopharyngioma with BAP1 and TP53 mutations. A literature review identified 44 cases of malignant craniopharyngiomas with a median overall survival of 6 months. Eighteen (41%) occurred in patients without any history of radiation, suggesting that mechanisms other than radiation have contributed to their ...
Thomas J. Auen, Isabella W. Zhang, Weiwei Zhang, Jordan M. Burr, Matthew L. Carda, James L. Wisecarver, Nicole Shonka, Jesse L. Cox, Sahara J. Cathcart, Allison Cushman‐Vokoun, Jie Chen   +10 more
wiley   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

The metalloproteinase ADAM17 promotes acute lung inflammatory responses during pancreatitis

British Journal of Pharmacology, EarlyView.
Background and Purpose Acute pancreatitis (AP) is a multifactorial upper gastrointestinal inflammatory disorder that in severe cases (~20% of all AP) is associated with substantial morbidity and mortality, the latter coincident with multiorgan dysfunction, particularly acute lung injury (ALI).
Shermin Chan, Karen Hon, Ruby E. Dawson, Teresa Weng, Jelena Solujic, Yu C. J. Chey, James D. Zuiani, Griffith B. Perkins, P. Toby Coates, Chris Drogemuller, Eddie Sanderlin, Lulu Huang, John Finnie, Stefan Rose‐John, Arash Badiei, Phan Nguyen, Brendan J. Jenkins, Mohamed I. Saad   +17 more
wiley   +1 more source

Expert opinion on the management of anemia in prostate cancer patients receiving PARP inhibitors. [PDF]

Can Urol Assoc J
Hanna L, O'Dwyer R, Hamilou Z, Noonan K, Doucette S, Sridhar SS.   +5 more
europepmc   +1 more source

SOD2‐Superoxide Metabolic Axis Regulates Mitophagy and Modulates TKIs Sensitivity in Head and Neck Squamous Cell Carcinoma

Cancer Science, EarlyView.
Our findings provide compelling evidence that the SOD2‐superoxide metabolic axis functions as a mitochondrial redox checkpoint that governs mitophagy and ultimately shapes TKI sensitivity. ABSTRACT Superoxide dismutase 2 (SOD2) has been implicated in head and neck squamous cell carcinoma (HNSCC), yet its mechanistic contribution in regulating tumor ...
Wan‐Hang Zhou, Shuo‐Jin Huang, An‐Xun Wang   +2 more
wiley   +1 more source

PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape. [PDF]

Cancer Med
Chen Y, Cao J, Huang R, Lou J, Gu J, Luo Z, Yao T, Xie J.   +7 more
europepmc   +1 more source

TONSL Promotes Hepatocellular Carcinoma Progression by Inhibiting Apoptosis Through Homologous Recombination Repair

Cancer Science, EarlyView.
In hepatocellular carcinoma, the 8q24.3 locus is frequently amplified and is associated with tumor‐specific overexpression of TONSL. TONSL promotes homologous recombination repair through RAD51, limits γH2AX accumulation and apoptosis, supports tumor growth, and its loss increases sensitivity to poly (ADP‐ribose) polymerase (PARP) inhibition.
Akinori Tsujimoto, Hajime Otsu, Takashi Ofuchi, Tomohiko Ikehara, Kosuke Hirose, Shohei Shibuta, Kazuki Omachi, Yu Takahashi, Yuya Ono, Satoshi Higuchi, Takanari Tatsumi, Kiyotaka Hosoda, Qingjiang Hu, Yusuke Yonemura, Takaaki Masuda, Masayuki Sho, Koshi Mimori   +16 more
wiley   +1 more source

APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell. [PDF]

Sci Rep
Rivera M, Liu L, Enlund S, Lim CE, Zhang H, Yang K, Sasik R, Crews LA, Fisch KM, Eskander RN, Holm F, Jiang Q.   +11 more
europepmc   +1 more source